Trials / Completed
CompletedNCT03311464
A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan
A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to investigate the efficacy, safety and pharmacokinetics of adalimumab in subjects in Japan with active ulcer(s) due to Pyoderma Gangrenosum (PG).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | adalimumab | Study drug will be administered subcutaneously. |
Timeline
- Start date
- 2017-10-27
- Primary completion
- 2019-08-20
- Completion
- 2020-04-21
- First posted
- 2017-10-17
- Last updated
- 2021-03-09
Locations
20 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03311464. Inclusion in this directory is not an endorsement.